{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T23:42:54Z","timestamp":1768434174548,"version":"3.49.0"},"reference-count":18,"publisher":"Innovative Healthcare Institute","issue":"3","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP)i are emerging as standard oncology treatments in various tumor types. The indications will expand as PARPi are being investigated in various breast cancer subtypes. Currently, except for BRCA1\/2 mutation carriers with human epidermal growth factor receptor 2 (HER2)-negative breast cancer, there is inadequate identification of predictive biomarkers of response. We present a 57-year-old woman with metastatic breast cancer, hormone-receptor-positive, HER2 negative with a germline ataxia-telangiectasia mutation with a large brain metastasis with clinical benefit to talazoparib. This case report exemplifies the importance of the multidisciplinary management of patients with brain metastases and personalized biomarker selected treatment.<\/jats:p>","DOI":"10.36401\/jipo-22-33","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T09:26:01Z","timestamp":1688117161000},"page":"158-161","source":"Crossref","is-referenced-by-count":2,"title":["Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation"],"prefix":"10.36401","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2944-9488","authenticated-orcid":true,"given":"Anca","family":"Chelariu-Raicu","sequence":"first","affiliation":[{"name":"1 Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"},{"name":"2 Department of Obstetrics and Gynecology, Breast Center, Gynecologic Oncology Center, and CCC Munich, LMU University Hospital, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[{"name":"3 Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Chavez-MacGregor","sequence":"additional","affiliation":[{"name":"4 Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"},{"name":"5 Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Johnson","sequence":"additional","affiliation":[{"name":"6 Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Sawaya","sequence":"additional","affiliation":[{"name":"7 Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Frances","family":"McAleer","sequence":"additional","affiliation":[{"name":"8 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissa","family":"Nguyen","sequence":"additional","affiliation":[{"name":"6 Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Hartnett","sequence":"additional","affiliation":[{"name":"3 Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolia M.","family":"Tsimberidou","sequence":"additional","affiliation":[{"name":"3 Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"3 Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA"},{"name":"9 Department of Breast Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA"},{"name":"10 The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ecaterina E.","family":"Dumbrava","sequence":"additional","affiliation":[{"name":"3 Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22027","published-online":{"date-parts":[[2023,6,28]]},"reference":[{"key":"2023081720134432800_i2590-017X-6-3-158-b01","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1200\/JCO.2004.01.175","article-title":"CNS metastases in breast cancer","volume":"22","author":"Lin","year":"2004","journal-title":"J Clin Oncol"},{"key":"2023081720134432800_i2590-017X-6-3-158-b02","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"key":"2023081720134432800_i2590-017X-6-3-158-b03","doi-asserted-by":"crossref","first-page":"163","DOI":"10.21037\/atm.2018.04.35","article-title":"Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies","volume":"6","author":"Brosnan","year":"2018","journal-title":"Ann Transl Med"},{"key":"2023081720134432800_i2590-017X-6-3-158-b04","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijrobp.2017.04.037","article-title":"A multi-institutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901 Study Update): irradiation-related complications and long-term maintenance of Mini-Mental State Examination scores","volume":"99","author":"Yamamoto","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023081720134432800_i2590-017X-6-3-158-b05","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA"},{"key":"2023081720134432800_i2590-017X-6-3-158-b06","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-811161-1.00002-5","article-title":"Brain metastases: epidemiology","volume":"149","author":"Ostrom","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"2023081720134432800_i2590-017X-6-3-158-b07","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/jon.12149","article-title":"Distinct MR imaging features of triple-negative breast cancer with brain metastasis","volume":"25","author":"Yeh","year":"2015","journal-title":"J Neuroimaging"},{"key":"2023081720134432800_i2590-017X-6-3-158-b08","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"2023081720134432800_i2590-017X-6-3-158-b09","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"key":"2023081720134432800_i2590-017X-6-3-158-b10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"2023081720134432800_i2590-017X-6-3-158-b11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/cancers12030687","article-title":"ATM-deficient cancers provide new opportunities for precision oncology","volume":"12","author":"Jette","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2023081720134432800_i2590-017X-6-3-158-b12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"2023081720134432800_i2590-017X-6-3-158-b13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41585-018-0129-3","article-title":"PARP inhibition\u2014not all gene mutations are created equal","volume":"16","author":"Luo","year":"2019","journal-title":"Nat Rev Urol"},{"key":"2023081720134432800_i2590-017X-6-3-158-b14","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.eururo.2019.02.002","article-title":"Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations","volume":"76","author":"Marshall","year":"2019","journal-title":"Eur Urol"},{"key":"2023081720134432800_i2590-017X-6-3-158-b15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2020.10.029","article-title":"Advanced prostate cancer with ATM loss: PARP and ATR inhibitors","volume":"79","author":"Neeb","year":"2021","journal-title":"Eur Urol"},{"key":"2023081720134432800_i2590-017X-6-3-158-b16","volume-title":"Cancer Clinical Trial Eligibility Criteria: Brain Metastases","year":"2019"},{"key":"2023081720134432800_i2590-017X-6-3-158-b17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41523-019-0139-1","article-title":"Response to olaparib in a patient with germline BRCA2 mutation and breast cancer leptomeningeal carcinomatosis","volume":"5","author":"Exman","year":"2019","journal-title":"NPJ Breast Cancer"},{"issue":"(Suppl 1)","key":"2023081720134432800_i2590-017X-6-3-158-b18","first-page":"i16","article-title":"MLTI-10. Establishment of a multidisciplinary brain metastasis clinic to facilitate patient-centered care and coordinated research","volume":"1","author":"Li","year":"2019","journal-title":"Neurooncol Adv."}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/6\/3\/158\/3250572\/i2590-017x-6-3-158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/6\/3\/158\/3250572\/i2590-017x-6-3-158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:18Z","timestamp":1765475298000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/6\/3\/article-p158.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,28]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,6,28]]},"published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-22-33","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,28]]}}}